<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <channel>
  <title>Daily CSR</title>
  <description><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></description>
  <link>https://www.dailycsr.com/</link>
  <language>us</language>
  <dc:date>2026-08-04T00:11:06+02:00</dc:date>
  <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="alternate" href="https://www.dailycsr.com/xml/atom.xml" type="text/xml" />
  <item>
   <guid isPermaLink="false">tag:https://www.dailycsr.com,2026:rss-97206688</guid>
   <title>Nona Biosciences and Lonza Partner to Advance BBB Technology for CNS Therapies</title>
   <pubDate>Thu, 02 Jul 2026 16:24:00 +0200</pubDate>
   <dc:language>us</dc:language>
   <dc:creator>Debashish Mukherjee</dc:creator>
   <dc:subject><![CDATA[Companies]]></dc:subject>
   <description>
   <![CDATA[
        <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/97206688-67725234.jpg?v=1783002516" alt="Nona Biosciences and Lonza Partner to Advance BBB Technology for CNS Therapies" title="Nona Biosciences and Lonza Partner to Advance BBB Technology for CNS Therapies" />
     </div>
     <div>
      <div style="text-align: justify;">Nona Biosciences ("Nona"), a biotechnology company focused on advancing biologics discovery and development through proprietary technology platforms, has announced a strategic partnership with Lonza to create advanced single-domain antibody-based blood-brain barrier (BBB) delivery technologies for the treatment of central nervous system (CNS) disorders. <br />   <br />  The collaboration will utilize Nona's proprietary Harbour Mice® fully human HCAb platform to identify and develop next-generation BBB-penetrating technologies based on single-domain antibodies. Recognized for its ability to generate fully human HCAbs and VHH binders with high affinity and favorable developability characteristics, the platform is expected to support the creation of a leading BBB delivery solution. This technology aims to facilitate the transport of a wide range of therapeutic agents into the CNS, opening new possibilities for CNS therapeutics and future licensing opportunities. Lonza will contribute its expertise in protein engineering, along with its GS Gene Expression System® and GlycoConnect® bioconjugation technologies, to optimize selected BBB-crossing candidates and expand their potential applications. <br />   <br />  According to the agreement, Nona will receive upfront and option-related payments from Lonza. In addition, both companies will share revenue generated from future licensing arrangements arising from the partnership. <br />   <br />  Dr. Jingsong Wang, Chairman of Nona Biosciences, stated that the collaboration reinforces the strength of Nona's technology platform and its strategic commitment to next-generation drug delivery solutions. He noted that Lonza's global presence, regulatory knowledge, and commercial manufacturing capabilities are expected to accelerate the advancement of Nona's BBB-crossing technology. He added that the partnership creates opportunities for licensing, commercialization, and long-term value generation while further strengthening Nona's position in CNS drug delivery and supporting improved patient outcomes. <br />   <br />  Dr. Di Hong, Chief Executive Officer of Nona Biosciences, said that the company is pleased to work with Lonza on the development and commercialization of innovative BBB-crossing technologies for CNS diseases. He emphasized that the collaboration highlights the versatility and capabilities of the HCAb Harbour Mice® platform in generating differentiated, fully human single-domain binders capable of overcoming some of the most complex challenges in drug delivery. By combining Nona's platform technologies with Lonza's development and manufacturing expertise, he expressed confidence that the partnership can deliver next-generation BBB solutions and create new therapeutic opportunities for patients affected by severe CNS disorders. <br />   <br />  Peter Droc, Head of Licensing at Lonza, stated that acquiring intellectual property rights related to Nona's BBB-crossing technology, together with the ongoing collaboration, will enable customers to more effectively advance promising CNS therapies into clinical and commercial applications. He added that combining the technology with Lonza's flexible CDMO services allows partners to engage at any stage of development—from technology licensing to integrated development and commercial-scale manufacturing—helping to simplify the process and accelerate the delivery of new treatments to patients.</div>  
     </div>
     <br style="clear:both;"/>
   ]]>
   </description>
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/97206688-67725234.jpg</photo:imgsrc>
   <link>https://www.dailycsr.com/Nona-Biosciences-and-Lonza-Partner-to-Advance-BBB-Technology-for-CNS-Therapies_a5931.html</link>
  </item>

  <item>
   <guid isPermaLink="false">tag:https://www.dailycsr.com,2026:rss-96391687</guid>
   <title>Danielle Kelvas, MD Explores Healthcare Marketing’s Impact on the Brain in New Book</title>
   <pubDate>Mon, 04 May 2026 15:13:00 +0200</pubDate>
   <dc:language>us</dc:language>
   <dc:creator>Debashish Mukherjee</dc:creator>
   <dc:subject><![CDATA[Companies]]></dc:subject>
   <description>
   <![CDATA[
        <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/96391687-67216416.jpg?v=1777900579" alt="Danielle Kelvas, MD Explores Healthcare Marketing’s Impact on the Brain in New Book" title="Danielle Kelvas, MD Explores Healthcare Marketing’s Impact on the Brain in New Book" />
     </div>
     <div>
      <div style="text-align: justify;">As federal regulators begin taking a closer look at the growing overlap between healthcare and consumer influence, one physician is bringing the issue into the national spotlight. Danielle Kelvas, MD has announced the upcoming release of <em>This Is Your Brain on Marketing</em>, a thoroughly researched and deeply personal work arguing that modern medical marketing has moved beyond persuasion and into the realm of biological influence. <br />   <br />  Planned for release in late 2026, the book arrives at a pivotal moment, as the Federal Trade Commission and its newly established Healthcare Task Force begin addressing misleading and manipulative healthcare practices. According to Dr. Kelvas, this level of oversight has been needed for years. <br />   <br />  “We’ve spent too long thinking of marketing as simple communication. In reality, it functions as behavioral neuroscience deployed on a massive scale,”said Danielle Kelvas, MD. <br />   <br />  Rather than presenting a purely argumentative stance, <em>This Is Your Brain on Marketing</em> examines how healthcare marketing systems can shape biology, behavior, and identity. Drawing from neuroscience, behavioral psychology, and clinical experience, Dr. Kelvas explains how modern marketing strategies can influence dopamine systems, interfere with hormonal balance, and gradually alter how individuals perceive themselves and their lives. <br />   <br />  The book follows a four-part structure — Becoming, Immersion, Rupture, and Reckoning — and applies these themes to major areas of health, including nutrition, sleep, weight management, mental wellness, and relationships. Throughout these discussions, Dr. Kelvas argues that many struggles people interpret as personal shortcomings are often biologically predictable responses to carefully engineered environments. <br />   <br />  “What many people see as a lack of willpower is often a normal biological reaction to environments intentionally designed to shape behaviour,”said Danielle Kelvas, MD. <br />   <br />  One especially controversial section explores how direct-to-consumer healthcare advertising has expanded the boundaries of diagnosis, turning ordinary emotional experiences into medicalized conditions while tying identity more closely to labels and treatments. Another chapter focuses on children, examining how marketing systems may affect developing brains, accelerate identity formation, and weaken long-term emotional resilience. <br />   <br />  At its core, the book makes both a scientific and ethical case. Dr. Kelvas argues that any system capable of consistently influencing human biology and behavior should be subject to the same level of scrutiny and accountability expected of other major medical interventions. <br />   <br />  “If a system can consistently shape biology and behavior, it deserves the same level of accountability as any other powerful medical intervention,”said Danielle Kelvas, MD. <br />   <br />  Dr. Kelvas views the FTC Healthcare Task Force as an important institutional acknowledgment that the environments influencing patient behavior may themselves contribute to widespread health challenges — a recognition that strongly aligns with the book’s central message. <br />   <br />  Ultimately, <em>This Is Your Brain on Marketing</em> is intended as a compassionate examination of modern healthcare systems and their impact on patients. After years in clinical practice watching individuals blame themselves for problems shaped by forces beyond their awareness, Dr. Kelvas hopes readers will better understand the systems influencing them — and stop seeing themselves as fundamentally flawed. <br />   <br />  “This book helps explain why so many people feel damaged or inadequate — and why they aren’t. I’m exhausted by hearing patients dismissed as simply ‘noncompliant,’” said Danielle Kelvas, MD.</div>  
     </div>
     <br style="clear:both;"/>
   ]]>
   </description>
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/96391687-67216416.jpg</photo:imgsrc>
   <link>https://www.dailycsr.com/Danielle-Kelvas-MD-Explores-Healthcare-Marketing-s-Impact-on-the-Brain-in-New-Book_a5760.html</link>
  </item>

 </channel>
</rss>
